Free Republic

A recent phase three study conducted by Eli Lilly examined the safety and efficacy of the study drug donanemab in participants with early Alzheimer's disease (AD). The pharmaceutical company Eli Lilly announced in a press release on May 3, 2023, that a clinical trial of the experimental Alzheimer's drug, donanemab, showed it could significantly slow the progress of cognitive decline, allowing patients increased independence. The drugmaker's announcement revealed that the drug succeeded in halting early AD progression in nearly half of the participants, slowing cognitive decline rates by 35% compared to control participants. Donanemab is an antibody that targets protein...

An experimental Alzheimer's drug developed by Eli Lilly and Co (LLY.N) slowed cognitive decline by 35% in a closely watched late-stage trial, the company said on Wednesday, raising hopes for a second effective treatment for the brain-wasting disease. (excerpt) The drug, donanemab, met all goals of the trial. It slowed progression of Alzheimer's by 35% to 36% compared to a placebo in 1,182 people diagnosed with early-stage disease based on scans showing brain deposits of amyloid protein and intermediate levels of tau protein, Lilly said.

Eli Lilly and Company's experimental intravenous drug donanemab could slow the cognitive decline of patients with Alzheimer's disease, according to early clinical trial results, published in The New England Journal of Medicine on Saturday. The study included 257 patients with early symptomatic Alzheimer's disease; 131 received donanemab, while 126 received a placebo. The researchers found donanemab slowed the decline of cognition and daily function in Alzheimer's patients by 32% after 76 weeks, compared to those who received a placebo. Taken over 18 months, that 32% slowing of decline could be noticeably impactful for Alzheimer's patients, noted Maria Carrillo, chief science...